JP2011517443A5 - - Google Patents

Download PDF

Info

Publication number
JP2011517443A5
JP2011517443A5 JP2011500192A JP2011500192A JP2011517443A5 JP 2011517443 A5 JP2011517443 A5 JP 2011517443A5 JP 2011500192 A JP2011500192 A JP 2011500192A JP 2011500192 A JP2011500192 A JP 2011500192A JP 2011517443 A5 JP2011517443 A5 JP 2011517443A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
substituents
hydrogen
defined above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011500192A
Other languages
English (en)
Japanese (ja)
Other versions
JP5504252B2 (ja
JP2011517443A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/053133 external-priority patent/WO2009115515A1/en
Publication of JP2011517443A publication Critical patent/JP2011517443A/ja
Publication of JP2011517443A5 publication Critical patent/JP2011517443A5/ja
Application granted granted Critical
Publication of JP5504252B2 publication Critical patent/JP5504252B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011500192A 2008-03-18 2009-03-17 5−ht6アンタゴニストとしてのアリールスルホニルピラゾリンカルボキシアミジン誘導体 Expired - Fee Related JP5504252B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3746308P 2008-03-18 2008-03-18
EP08152873.9 2008-03-18
US61/037,463 2008-03-18
EP08152873 2008-03-18
PCT/EP2009/053133 WO2009115515A1 (en) 2008-03-18 2009-03-17 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists

Publications (3)

Publication Number Publication Date
JP2011517443A JP2011517443A (ja) 2011-06-09
JP2011517443A5 true JP2011517443A5 (https=) 2012-04-26
JP5504252B2 JP5504252B2 (ja) 2014-05-28

Family

ID=39639064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011500192A Expired - Fee Related JP5504252B2 (ja) 2008-03-18 2009-03-17 5−ht6アンタゴニストとしてのアリールスルホニルピラゾリンカルボキシアミジン誘導体

Country Status (29)

Country Link
US (3) US8563723B2 (https=)
EP (2) EP2265589B1 (https=)
JP (1) JP5504252B2 (https=)
KR (1) KR101623357B1 (https=)
CN (2) CN104003937A (https=)
AR (1) AR070898A1 (https=)
AU (1) AU2009226956C1 (https=)
BR (1) BRPI0908738A8 (https=)
CA (1) CA2717922A1 (https=)
CO (1) CO6290679A2 (https=)
CR (1) CR11742A (https=)
DK (2) DK2610247T3 (https=)
DO (2) DOP2010000276A (https=)
EA (1) EA023176B1 (https=)
EC (1) ECSP10010476A (https=)
ES (2) ES2577867T3 (https=)
HK (1) HK1201823A1 (https=)
IL (1) IL207846A0 (https=)
MX (1) MX2010010299A (https=)
MY (1) MY155318A (https=)
NZ (1) NZ587743A (https=)
PH (1) PH12013502376A1 (https=)
PL (2) PL2265589T3 (https=)
PT (1) PT2610247T (https=)
SG (1) SG183688A1 (https=)
TW (1) TWI557110B (https=)
UA (1) UA105629C2 (https=)
WO (1) WO2009115515A1 (https=)
ZA (1) ZA201006272B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079935A1 (es) * 2010-01-29 2012-02-29 Abbott Healthcare Products Bv Sintesis de derivados de pirazolin carboxamidina sustituida
JP6122006B2 (ja) * 2011-08-15 2017-04-26 ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション ヒストン脱メチル化酵素阻害剤としての、置換された(e)−n’−(1−フェニルエチリデン)ベンゾヒドラジド類似体
WO2014078610A1 (en) * 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
CA2891535A1 (en) * 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
JP6322204B2 (ja) * 2012-11-16 2018-05-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ジヒドロピラゾールのgpr40モジュレーター
AU2015255765A1 (en) * 2014-05-09 2016-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators
CA2957566C (en) 2014-08-12 2023-08-01 Daniel Paul Becker Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same
EP3109237A1 (en) * 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN107460160A (zh) * 2017-08-23 2017-12-12 世贸天阶制药(江苏)有限责任公司 一种cho细胞无血清培养基
US10879709B2 (en) 2018-05-31 2020-12-29 National Taipei University Of Technology Power management system and operating method thereof
TW202128664A (zh) 2019-10-09 2021-08-01 德商拜耳廠股份有限公司 作為除害劑之新穎雜芳基三唑化合物
WO2022013225A1 (en) 2020-07-13 2022-01-20 Precirix N.V. Antibody fragment against folr1
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
CA3251753A1 (en) 2022-05-02 2023-11-09 Precirix N.V. PRE-TARGETTING

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20030913A2 (en) 2001-09-21 2004-06-30 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
SA07280510B1 (ar) * 2006-09-22 2012-02-07 سولفاي فارماسوتيكالز بي . في سلفونيل بيرازول ومشتقات سلفونيل كربوكساميدين كمضادات ht6-5

Similar Documents

Publication Publication Date Title
JP2011517443A5 (https=)
RU2470011C2 (ru) Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов
RU2286988C2 (ru) Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью
KR102160395B1 (ko) 벤조티오펜 화합물 또는 이의 염의 2수화물, 및 이의 제조 방법
JP2009538910A5 (https=)
JP2010520264A5 (https=)
JP2005526723A5 (https=)
JP2004527467A5 (https=)
JP2004518763A5 (https=)
JP4198989B2 (ja) セロトニン作動性薬
JP2019069966A (ja) Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
JP2002523508A5 (https=)
JP2010520265A5 (https=)
JP2010529045A5 (https=)
JP2011509309A5 (https=)
JP2010538001A5 (https=)
JP2011530521A5 (https=)
CN104193741A (zh) 作为α7-烟碱乙酰胆碱受体配体的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
US10023534B2 (en) Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK
JP2015508092A5 (https=)
JP2007500168A5 (https=)
JP2015531764A5 (https=)
JP2013526610A5 (https=)
JP2008542365A5 (https=)
EP2616460B1 (en) Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine.